Article Text

Download PDFPDF
Thoughts on the shortage of vinflunine: could we have done more?
  1. Ana Isabel Cachafeiro Pin1,
  2. Laura Villaverde Piñeiro2,
  3. Yveth Michelle Tajes Gonzalez1,
  4. Natalia Fernandez Nuñez3
  1. 1Pharmacy, Hospital Da Costa, Burela, Galicia, Spain
  2. 2Pharmacy, Hospital Comarcal de Monforte, Monforte de Lemos, Spain
  3. 3Oncology, University Hospital Lucus Augusti, Lugo, Galicia, Spain
  1. Correspondence to Mrs Laura Villaverde Piñeiro, Pharmacy, Hospital Comarcal de Monforte, Monforte de Lemos, Spain; lvillaverdepineiro{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

There are many causes of medicine shortages. Solutions are difficult to implement; these are global problems, meaning that exclusively national action has less chance of success than action on an international scale.1

Those most affected are patients who suffer interruption of their treatment or its replacement by less effective alternatives.

Vinflunine is indicated in monotherapy in adults with advanced or metastatic carcinoma of transitional cells of the urothelial tract previously treated with platinum derivatives.2

In June 2021, the supplier of vinflunine reported supply problems until March 2022. The Spanish Agency of Medicines and Medical Devices (AEMPS) started its distribution for those who were not suitable candidates for immunotherapy. Its shortage is …

View Full Text

Footnotes

  • Twitter @anaicp, @lvilpin1

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.